Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tämä on Roche P-tutkimusten laajennustutkimus okrelitsumabin turvallisuuden ja tehokkuuden tutkimiseksi potilailla, joilla on multippeliskleroosi (MS)

perjantai 28. elokuuta 2026 päivittänyt: Hoffmann-La Roche

Yksihaarainen, avoin monikeskustutkimus okrelitsumabin tehokkuuden ja turvallisuuden arvioimiseksi multippeliskleroosia sairastavilla potilailla, jotka olivat aiemmin osallistuneet F. Hoffmann-La Rochen sponsoroimiin okrelitsumabin vaiheen IIIb/IV kliinisiin tutkimuksiin

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).

Tutkimuksen yleiskatsaus

Tila

Valmis

Interventio / Hoito

Yksityiskohtainen kuvaus

This is a single arm, open label, multicenter extension study in participants who completed treatment period with ocrelizumab in the Roche P-trials. Participants will receive treatment with ocrelizumab as single 600 mg infusions every 24 weeks for two years.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

1055

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • 's-Hertogenbosch, Alankomaat, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Amsterdam, Alankomaat, 1081 HV
        • Amsterdam UMC Location VUMC
      • Breda, Alankomaat, 4819 EV
        • Amphia Ziekenhuis
      • Gouda, Alankomaat, 2803 HH
        • Groene Hart Ziekenhuis
      • NL -rotterdam, Alankomaat, 3079 DZ
        • Maasstadziekenhuis
      • Sittard-Geleen, Alankomaat, 6162 BG
        • Zuyderland Medisch Centrum - Sittard Geleen
      • Tilburg, Alankomaat, 5022 GC
        • Elisabeth-TweeSteden Ziekenhuis
      • Buenos Aires, Argentiina, C1437JCP
        • Hospital Churruca Visca
      • Ciudad Autonoma Buenos Aires, Argentiina, C1061ABD
        • Centro de Especialidades Neurológicas y Rehabilitación - CENyR
      • Rosario, Argentiina, 2000
        • Fundacion Rosarina de Neurorehabilitacion
      • Bruges, Belgia, 8000
        • AZ Sint Jan
      • Edegem, Belgia, 2650
        • UZ Antwerpen
      • La Louvière, Belgia, 7100
        • CHU Tivoli
      • Liège, Belgia, 4000
        • CHU de Liège (Sart Tilman)
      • Overpelt, Belgia, 3900
        • Revalidatie en MS Centrum
    • Paraná
      • Curitiba, Paraná, Brasilia, 81210-310
        • Instituto de Neurologia de Curitiba
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilia, 90610-000
        • Hospital Sao Lucas - PUCRS
    • São Paulo
      • São Paulo, São Paulo, Brasilia, 05403-900
        • Hospital das Clinicas - FMUSP
      • Sofia, Bulgaria, 1113
        • Shat Np Sveti Naum
      • Sofia, Bulgaria, 1309
        • Multiprofile Hosp. for Active Treatment
      • Barcelona, Espanja, 08035
        • Hospital Vall d'Hebron
      • Cadiz, Espanja, 11009
        • Hospital Puerta del Mar
      • Girona, Espanja, 17007
        • Hospital Universitari de Girona Dr. Josep Trueta
      • Madrid, Espanja, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Espanja, 28046
        • Hospital Universitario La Paz
      • Madrid, Espanja, 28006
        • Universitario de La Princesa
      • Madrid, Espanja, 28040
        • Hospital Universitario Clínico San Carlos
      • Murcia, Espanja
        • Hospital Universitario Virgen de Arrixaca
      • Seville, Espanja, 41009
        • Hospital Universitario Virgen Macarena
      • Valencia, Espanja, 46010
        • Hospital Clinico Universitario de Valencia
      • Valencia, Espanja, 46026
        • Hospital Universitario la Fe
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Espanja, 08907
        • Hospital Universitari de Bellvitge
    • Castellon
      • Castellon, Castellon, Espanja, 12004
        • Hospital General de Castellon
    • LA Coruna
      • A Coruña, LA Coruna, Espanja, 15006
        • Complejo Hospitalario Universitario A Coruña (CHUAC)
    • Lerida
      • Lleida, Lerida, Espanja, 25198
        • Hospital Universitari Arnau de Vilanova de Lleida
    • Madrid
      • Pozuelo de Alarcón, Madrid, Espanja, 28223
        • Hospital Quiron de Madrid
    • Pontevedra
      • Vigo, Pontevedra, Espanja, 36312
        • Complejo Hospitalario Universitario de Vigo - Xeral Cies
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Espanja
        • Hospital Universitario Central de Asturias
      • Dublin, Irlanti
        • St Vincents University Hospital
    • Abruzzo
      • Chieti, Abruzzo, Italia, 66013
        • Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla
      • L’Aquila, Abruzzo, Italia, 67100
        • Ospedale San Salvatore
    • Apulia
      • San Giovanni Rotondo, Apulia, Italia, 71013
        • IRCCS Ospedale Casa Sollievo Della Sofferenza
    • Campania
      • Naples, Campania, Italia, 80131
        • A. O. U. Federico II
      • Naples, Campania, Italia, 80131
        • Università degli Studi della Campania Luigi Vanvitelli
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italia, 40139
        • Ospedale Bellaria
    • Lazio
      • Rome, Lazio, Italia, 00168
        • Policlinico Universitario A. Gemelli
      • Rome, Lazio, Italia, 00189
        • Azienda Ospedaliera Sant'Andrea
      • Rome, Lazio, Italia, 00152
        • Ospedale S.Camillo Forlanini
      • Rome, Lazio, Italia, 00133
        • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
    • Liguria
      • Genoa, Liguria, Italia, 16132
        • Irccs A.O.U.San Martino Ist
    • Lombardy
      • Bergamo, Lombardy, Italia, 24127
        • ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
      • Gallarate, Lombardy, Italia, 21013
        • Ospedale S.Antonio Abate
      • Milan, Lombardy, Italia, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, Lombardy, Italia, 20133
        • Fond. Istituto Neurologico C.Besta
      • Milan, Lombardy, Italia, 20122
        • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
      • Montichiari, Lombardy, Italia, 25018
        • Ospedale Civile di Montichiari
      • Pavia, Lombardy, Italia, 27100
        • IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla
    • Molise
      • Pozzilli, Molise, Italia, 86077
        • IRCCS Istituto Neurologico Neuromed
    • Sardinia
      • Cagliari, Sardinia, Italia, 09126
        • Ospedale Binaghi
    • Sicily
      • Catania, Sicily, Italia, 95123
        • AOU Policlinico V. Emanuele - P.O G. Rodolico
      • Cefalù, Sicily, Italia, 90015
        • Fondazione Istituto S. Raffaele - Giglio
      • Palermo, Sicily, Italia, 90129
        • AOU Policlinico Giaccone
      • Palermo, Sicily, Italia, 90146
        • AO Ospedali Riuniti Villa Sofia-Cervello
    • The Marches
      • Ancona, The Marches, Italia, 60100
        • AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi
    • Tuscany
      • Florence, Tuscany, Italia, 50134
        • AOUC Azienda Ospedaliero-Universitaria Careggi
      • Florence, Tuscany, Italia, 50134
        • AOU Careggi
      • Siena, Tuscany, Italia, 53100
        • AOU Senese - Presidio Ospedaliero Le Scotte
    • Umbria
      • Perugia, Umbria, Italia, 06156
        • AO di Perugia - Ospedale S. Maria della Misericordia
    • Veneto
      • Padova, Veneto, Italia, 35128
        • Azienda Ospedaliera di Padova
      • Verona, Veneto, Italia, 37134
        • Policlinico G.B. Rossi
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6T 1Z4
        • University of British Columbia
    • Ontario
      • London, Ontario, Kanada, N6A 5A5
        • London Health Sciences Centre Uni Campus
      • Ottawa, Ontario, Kanada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Toronto, Ontario, Kanada, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Gatineau, Quebec, Kanada, J8Y 1W2
        • Clinique NeuroOutaouais
      • Greenfield Park, Quebec, Kanada, J4V 2J2
        • Recherche Sepmus Inc.
      • Montreal, Quebec, Kanada, H3A 2B4
        • Montreal Neurological Institute and Hospital
      • Zagreb, Kroatia, 10000
        • Clinical Hospital Centre Zagreb
      • Kuwait City, Kuwait, 10002
        • Ibn Sina Hospital
      • Mexico City, Meksiko, 14050
        • Unidad de investigacion en salud (UIS)
    • Mexico CITY (federal District)
      • Mexico City, Mexico CITY (federal District), Meksiko, 06726
        • Hospital General de México
    • Sinaloa
      • Culiacán, Sinaloa, Meksiko, 80020
        • Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC
      • Bergen, Norja, 5021
        • Haukeland universitetssykehus
      • Drammen, Norja, 3004
        • Sykehuset Buskerud HF
      • Stavanger, Norja, 4011
        • Stavanger Universitetssykehus, Helse Stavanger HF
      • Braga, Portugali, 4710-243
        • Hospital de Braga
      • Coimbra, Portugali, 3000-075
        • HUC
      • Loures, Portugali, 2674-514
        • Hospital Beatriz Angelo
      • Porto, Portugali, 4099-001
        • Hospital Geral de Santo Antonio
      • Bydgoszcz, Puola, 85-796
        • Neurocentrum Bydgoszcz sp. z o.o
      • Gdansk, Puola, 80-803
        • COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika
      • Katowice, Puola, 40-568
        • Care Clinic
      • Krakow, Puola, 31-637
        • Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o.
      • Lodz, Puola, 90-324
        • Centrum Neurologii Krzysztof Selmaj
      • Lublin, Puola, 20-410
        • Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.
      • Warsaw, Puola, 02-097
        • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
      • Warsaw, Puola, 02-957
        • Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
      • Besançon, Ranska, 25030
        • CHU de Besancon Hopital Jean Minjoz
      • Bordeaux, Ranska, 33076
        • Groupe Hospitalier Pellegrin
      • Bron, Ranska, 69677
        • Hopital neurologique Pierre Wertheimer - CHU Lyon
      • Clermont-Ferrand, Ranska, 63003
        • Hopital Gabriel Montpied CHU de Clermont-Ferrand
      • Gonesse, Ranska, 95503
        • CH de Gonesse
      • La Tronche, Ranska, 38700
        • CHU de Grenoble
      • Lille, Ranska, 59037
        • Hopital Roger Salengro Service de Neurologie
      • Marseille, Ranska, 13005
        • CHU de la Timone - Hopital d Adultes
      • Montpellier, Ranska, 34295
        • Hopital Gui de Chauliac
      • Nancy, Ranska, 54035
        • Hopital Central - CHU de Nancy
      • Nantes, Ranska, 44805
        • Hôpital Guillaume et René Laënnec
      • Nice, Ranska, 06002
        • Hôpital Pasteur
      • Nîmes, Ranska, 30900
        • CHU de Nîmes Hopital Caremeau
      • Paris, Ranska, 75651
        • Groupe Hospitalier Pitié- Salpétrière
      • Poissy, Ranska, 78300
        • Hôpital de Poissy
      • Rouen, Ranska, 76031
        • CHU de Rouen Hopital
      • Strasbourg, Ranska, 67098
        • Höpital Hautepierre
      • Toulon, Ranska, 83041
        • HIA de Toulon hôpital militaire
      • Gothenburg, Ruotsi, 413 45
        • Sahlgrenska Sjukhuset
      • Karlstad, Ruotsi, 65185
        • Centralsjukhuset
      • Stockholm, Ruotsi, 113 41
        • Centrum för Neurologi
      • Bratislava, Slovakia, 813 69
        • Univerzitna nemocnica Bratislava
      • Bratislava, Slovakia, 826 06
        • Univerzitna nemocnica Bratislava Nemocnica Ruzinov
      • Trnava, Slovakia, 917 75
        • Fakultna nemocnica Trnava
      • Ljubljana, Slovenia, 1000
        • University Medical Centre
      • Maribor, Slovenia, 2000
        • University Medical Centre Maribor
      • Turku, Suomi, 20520
        • Mehiläinen Neo Turku
      • Aalborg, Tanska, 9000
        • Aalborg Universitetshospital
      • Aarhus N, Tanska, 8200
        • Aarhus Universitetshospital
      • Glostrup Municipality, Tanska, 2600
        • Rigshospitalet Glostrup
      • Odense C, Tanska, 5000
        • Odense Universitetshospital, Neurologisk Afdeling N
      • Sønderborg, Tanska, 6400
        • Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
      • Ankara, Turkki (Türkiye), 06500
        • Gazi University Medical Faculty
      • Ankara, Turkki (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Hatay, Turkki (Türkiye), 31001
        • Mustafa Kemal Ataturk UTF
      • Istanbul, Turkki (Türkiye), 34098
        • Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi
      • Istanbul, Turkki (Türkiye), 34093
        • Istanbul University Istanbul School of Medicine
      • Konya, Turkki (Türkiye), 42131
        • Selcuk University Medical Faculty
      • Samsun, Turkki (Türkiye), 55139
        • Ondokuz Mayis University School of Medicine
      • Trabzon, Turkki (Türkiye), 61080
        • Karadeniz Tecnical Uni. Med. Fac.
      • Brno, Tšekki, 656 91
        • Fakultni nemocnice u sv. Anny
      • Jihlava, Tšekki, 58633
        • Nemocnice Jihlava
      • Prague, Tšekki, 12808
        • VFN Praha Poliklinika Rs Centrum - Budova A
      • Prague, Tšekki, 150 06
        • Fakultni nemocnice v Motole
      • Budapest, Unkari, 1204
        • Budapesti Jahn Ferenc Dél-pesti Kórház és Rendel?intézet
      • Esztergom, Unkari, 2500
        • VALEOMED Diagnosztikai Központ
      • Tallinn, Viro, 10138
        • East Tallinn Central Hospital
      • Tallinn, Viro, 10617
        • West Tallinn Central Hospital
      • Tartu, Viro, 51014
        • Tartu University Hospital
      • Exeter, Yhdistynyt kuningaskunta, EX2 5DW
        • Royal Devon and Exeter Hospital (Wonford)
      • Glasgow, Yhdistynyt kuningaskunta, G51 4TF
        • Queen Elizabeth University Hospital
      • Inverness, Yhdistynyt kuningaskunta, IV2 3UV
        • Raigmore Hospital
      • Leeds, Yhdistynyt kuningaskunta, LS9 7AU
        • Leeds Teaching Hospitals NHS Trust
      • London, Yhdistynyt kuningaskunta, SW17 0QT
        • St George's Hospital
      • London, Yhdistynyt kuningaskunta, W6 8RF
        • Charing Cross Hospital
      • London, Yhdistynyt kuningaskunta, SE5 9RS
        • Kings College Hospital
      • London, Yhdistynyt kuningaskunta, E1 1BB
        • The Royal London Hospital
      • London, Yhdistynyt kuningaskunta, NW3 2QS
        • Royal Free Hospital
      • London, Yhdistynyt kuningaskunta, WC1 3BG
        • National Hospital for Neurology and Neurosurgery,
      • Newcastle upon Tyne, Yhdistynyt kuningaskunta, NE1 4LP
        • Royal Victoria Infirmary
      • Salford, Yhdistynyt kuningaskunta, M6 8HD
        • Salford Royal NHS Foundation Trust
      • Sheffield, Yhdistynyt kuningaskunta, S10 2JF
        • Royal Hallamshire Hospita
      • Swansea, Yhdistynyt kuningaskunta, SA6 6NL
        • Morriston Hospital
      • Truro, Yhdistynyt kuningaskunta, TR1 3LQ
        • Royal Cornwall Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 65 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Signed Informed Consent Form
  • Able to comply with the study protocol, in the investigator's judgment
  • Completed the treatment period of Roche sponsored ocrelizumab P-trials

Exclusion Criteria:

  • Hypersensitivity to ocrelizumab or to any of its excipients.
  • Participantss in a severely immunocompromised state until the condition resolves.
  • Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation.
  • Existence of a contra-indication as per SmPC
  • Prohibited concomitant medication as specified in protocol
  • Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Ocrelizumab

Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.

Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline Expanded Disability Status Scale (EDSS) score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using Kaplan-Meier(K-M) method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to Onset of CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to Onset of CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to Onset of CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had Confirmed Disability Improvement (CDI) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated &scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDI Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated &scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at two scheduled visits at least 48 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at two scheduled visits at least 48 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had Improved, Stable or Worsened Disability Compared With CASTING Baseline in EDSS Category at LIBERTO Week 96
Aikaikkuna: At LIBERTO Week 96

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Participants were considered stable when the change from baseline in score was between -0.5 and +0.5, worsened when the change was > 0.5, and improved when the change in score was < -0.5. Percentages are rounded off.

At LIBERTO Week 96
Percentage of Participants Who Had Stable or Worsened Disability Compared With ENSEMBLE Baseline in EDSS Category at LIBERTO Week 96
Aikaikkuna: At LIBERTO Week 96

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Participants were considered stable when the change from baseline in score was between -0.5 and +0.5 and worsened when the change was > 0.5. Percentages are rounded off.

At LIBERTO Week 96
Change From CASTING Baseline in EDSS Score to LIBERTO Week 96
Aikaikkuna: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM).

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in EDSS Score to LIBERTO Week 96
Aikaikkuna: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Estimates are from analysis based on MMRM.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 25-foot Walk Test (T25FWT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 24-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 48-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 9 Hole Peg Test (9HPT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 24-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 48-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 24-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 48-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 24-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 48-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Time to First Protocol-Defined Event of Disease Activity
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disease activity was defined as at least one the following events: protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to MS. Symptoms must persist for > 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications), and immediately be preceded by neurological stability for at least 30 days.); 24 weeks CDP based on increases in EDSS; a new T1 Gadolinium (Gd)-enhanced lesion; or a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI). The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to First Relapse
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

A protocol-defined MS relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/ FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. or ≥1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Annualized Protocol-Defined Relapse Rate
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

ARR=total number of relapses for all participants divided by the total years of drug exposure (from first day of infusion in parent study until LIBERTO week 96). Protocol-defined MS relapse=occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours & not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on 1 of the FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual or ≥1 point on 2 or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. EDSS scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Adjusted ARR is reported.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Relapse Free Participants
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

A protocol-defined MS relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/ FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. or ≥1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Protocol-Defined Event of Disease Activity (NEDA) for CASTING Rollover Cohort
Aikaikkuna: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Percentage of participants with NEDA where disease activity = at least 1 of the following events: protocol defined relapse (PDR); 24 weeks CDP based on increases in EDSS while on treatment with ocrelizumab; a T1 Gd-enhanced lesion on MRI; or a new and/or enlarging T2 hyperintense lesion on MRI. PRD as defined in outcome measure 22. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS was 5.5 or less, and ≥ 0.5 when BS was above 5.5. Participants with EDSS of 0, progression was defined aschange of ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants With NEDA for ENSEMBLE Cohort
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEDA where disease activity = at least 1 of the following events: protocol defined relapse (PDR); 24 weeks CDP based on increases in EDSS while on treatment with ocrelizumab; a T1 Gd-enhanced lesion on MRI; or a new and/or enlarging T2 hyperintense lesion on MRI. PRD as defined in outcome measure 22. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS was 5.5 or less, and ≥ 0.5 when BS was above 5.5. Participants with EDSS of 0, progression was defined aschange of ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death).

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Evidence of Progression (NEP) From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEP =no progression sustained for at least 24 weeks on: CDP; 20% increase in timed T25FWT; 20% increase in timed 9HPT yearly & over the course of the study. CDP= increase of ≥ 1.0 point from the baseline EDSS score when BS= 5.5 or less, & ≥ 0.5 when the BS= above 5.5. For participants with an EDSS of 0, progression=change ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). In T25FWT test participants walked to a 25 foot course as quickly & safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. In T25FWT & 9-HPT the longer it took complete test= higher scores, indicating deterioration.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Evidence of Progression Sustained for at Least 24 Weeks and Disease Activity (NEPAD) From ENSEMBLE Baseline ENSEMBLE to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEPAD=no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse & no enlarging or new T2/ T1 Gd-enhancing lesion yearly & over the course of treatment. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS= 5.5 or less, & ≥ 0.5 when BS= above 5.5. Participants with EDSS of 0, progression=change ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death). In T25FWT test participants walked 25-foot course as quickly & safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. In T25FWT & 9-HPT the longer it took to complete test= higher scores, indicating deterioration.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From Baseline in Symbol Digit Modalities Test (SDMT) Score for CASTING Rollover Cohort
Aikaikkuna: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

SDMT test consists of a sequence of 110 symbols to be displayed in a maximum 90 seconds and a reference key legend (3 versions are available) with 9 symbols in a given order and their respective matching digits from 1 to 9. This test measures the speed (number of correct paired responses) to pair abstract symbols with specific digits in 90 seconds time. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to 8-point Improvement Change in the SDMT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
Aikaikkuna: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

SDMT test consists of a sequence of 110 symbols to be displayed in a maximum 90 seconds and a reference key legend (3 versions are available) with 9 symbols in a given order and their respective matching digits from 1 to 9. This test measures the speed (number of correct paired responses) to pair abstract symbols with specific digits in 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and a minimum of 0. Higher scores indicate improvement.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Rate of Gadolinium-enhancing Lesions on T1Gd+ Lesions as Detected by Brain MRI
Aikaikkuna: From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of T1 Gd-enhanced lesions for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Rate of New or Enlarging T2 Lesions as Detected by Brain MRI
Aikaikkuna: From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of new and/or enlarging T2 lesions for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Change in Total T1 Hypointense Lesion Volume Detected by Brain MRI
Aikaikkuna: At LIBERTO Week 96

Estimates are from analysis based on mixed-effect model of repeated measures (MMRM)

At LIBERTO Week 96
Rate of Fluid-Attenuated Inversion Recovery (FLAIR) Late Enhancing Lesions With Leakage as Detected by Brain MRI Over Time
Aikaikkuna: From LIBERTO Week 24 to LIBERTO Week 96; From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of FLAIR for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From LIBERTO Week 24 to LIBERTO Week 96; From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Percentage Change in Brain Volume as Detected by Brain MRI Over Time
Aikaikkuna: From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Percentage Change in White Matter Volume as Detected by Brain MRI Over Time
Aikaikkuna: From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Percentage Change in Cortical Grey Matter Volume as Detected by Brain MRI Over Time
Aikaikkuna: From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE Week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Time to Treatment Discontinuation
Aikaikkuna: From LIBERTO Baseline to LIBERTO Week 96 (up to 6 years)
From LIBERTO Baseline to LIBERTO Week 96 (up to 6 years)
Mean Work Productivity and Activity Impairment (WPAI) Score for CASTING Rollover Cohort
Aikaikkuna: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The WPAI employment status questionnaire is a PRO consisting of 6 items that assess working status, specifically the impact of MS on absenteeism, presentism, work productivity loss and activity impairment over the past 7 days. Four sub scores are calculated and presented as a percentage. Absenteeism = percent work time missed due to problem; Presenteeism = percent impairment while working due to problem; Work productivity= percent overall work impairment due to problem; Activity Impairment = percent activity Impairment due to problem). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Mean WPAI Score for ENSEMBLE Rollover Cohort
Aikaikkuna: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The WPAI employment status questionnaire is a PRO consisting of 6 items that assess working status, specifically the impact of MS on absenteeism, presentism, work productivity loss and activity impairment over the past 7 days. Four sub scores are calculated and presented as a percentage. Absenteeism = percent work time missed due to problem; Presenteeism = percent impairment while working due to problem; Work productivity= percent overall work impairment due to problem; Activity Impairment = percent activity Impairment due to problem). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in SymptoMScreen Score to LIBERTO Week 96
Aikaikkuna: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The SymptoMScreen comprises 12 distinct domains representing common MS symptoms: mobility, dexterity, vision, fatigue, cognition, bladder function, sensation, dizziness, spasticity, body pain, depression, and anxiety. Limitations associated with each symptom are rated on a 7-point Likert scale ranging from 0 ("not affected at all") to 6 ("total limitation; I am unable to perform most daily activities"). Domain scores are summed to generate a total score ranging from 0 to 72, with higher scores indicating greater symptom-related limitations.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in SymptoMScreen Score to LIBERTO Week 96
Aikaikkuna: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The SymptoMScreen comprises 12 distinct domains representing common MS symptoms: mobility, dexterity, vision, fatigue, cognition, bladder function, sensation, dizziness, spasticity, body pain, depression, and anxiety. Limitations associated with each symptom are rated on a 7-point Likert scale ranging from 0 ("not affected at all") to 6 ("total limitation; I am unable to perform most daily activities"). Domain scores are summed to generate a total score ranging from 0 to 72, with higher scores indicating greater symptom-related limitations.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in Multiple Sclerosis Impact Scale (MSIS-29), Physical Scale Score to LIBERTO Week 96
Aikaikkuna: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The MSIS-29 version 2 (MSIS-29v2) is a 29-item patient-reported outcome (PRO) measure designed to assess the physical and psychological impact of MS. The Physical Scale consists of 20 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw physical impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better health-related quality of life (HRQoL).

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in MSIS-29, Physical Scale Score to LIBERTO Week 96
Aikaikkuna: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Physical Scale consists of 20 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw physical impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in MSIS-29, Psychological Scale Score to LIBERTO Week 96
Aikaikkuna: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Psychological Scale consists of 9 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in MSIS-29, Psychological Scale Score to LIBERTO Week 96
Aikaikkuna: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Psychological Scale consists of 9 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Number of Participants With Adverse Events (AEs)
Aikaikkuna: From CASTING Baseline to LIBERTO SFU (up to 4.9 years); From ENSEMBLE Baseline to LIBERTO SFU (up to 6.9 years)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

From CASTING Baseline to LIBERTO SFU (up to 4.9 years); From ENSEMBLE Baseline to LIBERTO SFU (up to 6.9 years)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Clinical Trials, Hoffmann-La Roche

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 12. heinäkuuta 2018

Ensisijainen valmistuminen (Todellinen)

Torstai 17. heinäkuuta 2025

Opintojen valmistuminen (Todellinen)

Torstai 17. heinäkuuta 2025

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 25. kesäkuuta 2018

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 23. heinäkuuta 2018

Ensimmäinen Lähetetty (Todellinen)

Torstai 26. heinäkuuta 2018

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 25. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 28. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • MN39158
  • 2017 (Yhdysvaltain NIH-apuraha/sopimus)
  • 2017-004886-29 (EudraCT-numero)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa